ERBB2 and breast neoplasm: This study shows the therapeutic value of EV20/MMAF, a HER3‐targeted antibody‐drug conjugate loaded with monomethyl auristatin F, for the treatment of breast tumors refractory to conventional anti‐HER2 therapies.